A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)

Trial Profile

A Multi-Center, Double Blind, Placebo-Controlled, Randomized Phase II Trial of Gemcitabine Plus GDC-0449 (NSC 747691), a Hh Pathway Inhibitor, in Patients With Metastatic Pancreatic Cancer (10052747)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Vismodegib (Primary) ; Gemcitabine
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Jun 2017 Results (n=72) assessing molecular alterations in the circulating tumor DNA of advanced pancreatic cancer patients, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Nov 2015 Results published in the Journal of Clinical Oncology
    • 04 Jun 2013 Primary endpoint 'Progression-free-survival-duration' has not been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top